Levitee Labs announces agreement with Adracare, a WELL


VANCOUVER, British Columbia, October 18, 2021 (GLOBE NEWSWIRE) – Levitee Labs Inc. (the “Society” Where “Levite Laboratories“) (CSE: LVT) (OTC: LVTTF) (FSE: 7H7) an integrative wellness company with a diverse portfolio of healthcare and wellness assets, is pleased to announce a partnership with Adracare Inc. (“Adracare”) A Well Health Technologies (TSX: WELL) company (“GOOD Health” Where “GOOD“). WELL, an innovative healthcare company whose overriding goal is to leverage technology to empower and support healthcare professionals and their patients, will provide Levitee Labs Inc. with access to comprehensive disease management tools. WELL’s end-to-end practice, including, but not limited to, a world-class telemedicine platform. Levitee Labs is thrilled to join the WELL Health network for the opportunity to further strengthen its health and wellness assets.

“We believe that Adracare is a world-class partner with which to build an integrated telemedicine and technology platform, with the aim of delivering psychedelically inspired drugs and experimental therapies combined with digital therapies,” said Pouya Farmand , CEO of Levitee Labs. Levitee Labs operates 5 clinics and 3 pharmacies (primarily based in Alberta), which see approximately 35,000 patients per year. By bringing psychedelic medicine services into traditional healthcare infrastructure, Levitee Labs will be able to accurately assess the impact of psychedelic therapies on patients. Adracare’s technology platform provides services such as video conferencing, which make mental health services more accessible for patients and reduce the costs of providing care for healthcare providers. The Adracare platform unifies several core functionalities under one platform for Levitee Labs. This provides a single point of entry for patients to receive digital value-based care and allows providers to closely follow patients throughout their recovery process.

Levitee Labs recognizes that mental health assets are not digitized and optimally protected. Through this agreement with Adracare, Levitee Labs seeks to leverage Adracare’s technological tools to provide a cutting-edge digital technology platform for the delivery of mental health care. This model will integrate the ethical considerations of digital technologies into a platform that includes clinical workflows, evidence-based care, and shared decision-making in a sustainable and scalable manner. This platform will also be an opportunity for Levitee Labs to expand psychedelic therapies to various communities across Canada, where there is a critical shortage of in-person caregivers.

The agreement with Adracare will further enhance Levitee Labs’ ability to engage with its patients who bear the burden of addiction and mental health issues by improving workflows and interactions with them as well as their healthcare providers. care. As Levitee Labs continues to grow its portfolio of assets through an accretive M&A strategy, its growing number of patients with addictions and mental health issues will likely have multiple associated issues that need to be addressed. By partnering with Adracare, Levitee Labs now has a telehealth strategy and platform to provide care to more patients and cover a range of multidisciplinary addiction and mental health services, including individual counseling, group therapy, counseling and psychedelic treatment. .

Shervin Bakhtiari, Managing Director of Digital Health Applications at WELL, said: “We are delighted to partner with Levitee Labs, to provide them with a premier digital platform to support their growth. Adracare provides a robust turnkey practice management platform with native telehealth and patient engagement capabilities to deliver a personalized experience for mental healthcare providers and patients.

Through the use of Adracare’s telehealth solution, a wide range of services can also be performed at home, offering patients the ability to stay in place in a comfortable setting, removing barriers to accessibility. Appointments are made online, patient communications are sent via email and SMS, and a virtual tour can take place, all within the same technology platform.

About Levitee Labs Inc.

Levitee Labs is establishing itself as a leader in the field of integrative wellness. By leveraging a M&A regime focused on centralizing complementary integrative wellness assets, Levitee Labs aims to transform mental health and addiction treatments through the integration of psychedelic medicines and alternative therapies. . The company’s current portfolio of assets includes: Levitee Clinics ™, a group of five drug and pain treatment clinics in Alberta; Levitee Pharmacies ™, three pharmacies operating in Alberta specializing in dispensing prescriptions for patients with substance use disorders, mental health issues and chronic pain; BlockMD, Alberta’s first tech company to receive provincial approval for electronic drug prescriptions; and Earth Circle Organics, a direct-to-consumer supplements and superfoods wholesaler with over 180 references in its product line across three brands. Further information on Levitee Labs is available on its website at www.leviteelabs.com.

About Adracare Inc.

Adracare is a complete yet simple virtual clinical solution designed for outpatient clinics, from small practices to businesses. The platform is designed for specialty clinics, but optimizes and focuses on patient engagement. We’re on a mission to reduce workflow inefficiencies, providing organized workflows tailored to each specialty practice. By eliminating manual processes, optimizing data access, and integrating with other critical healthcare platforms, we save clinics time and money. Our suite of tools includes video conferencing, easy online booking and messaging, in-session mapping and many other features that unify practice management while making healthcare more accessible and convenient. Please visit our Facebook page at https://www.facebook.com/adracare and our website at https://adracare.com/ for more details.

Forward-looking statements

This press release contains certain statements that may constitute forward-looking information under applicable securities laws. All statements, other than those of historical fact, that deal with activities, events, results, developments, performance or achievements that Levitee Labs anticipates or expects to occur or will occur in the future (in whole or in part) should be considered as going forward – seeking information. Such information may involve, without limitation, statements regarding the business plans and offered products of Levitee Labs, as well as the benefits derived from mushroom infused products. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is planned”, “budget”, “planned”, “estimates”, “forecasts”, ” means “,” anticipates “or” believes “or variations (including negative variations) of these words and expressions, or statements made in the future or indicating that certain actions, events or results” could “,” could “,” would be “,” could “or” will “(or other variations of the above) either taken, to occur, to be achieved or to be realized. These statements and other forward-looking information are based on assumptions made by Levitee Labs based on competitive, financial and economic data and operating plans, strategies or beliefs currently available as of the date of this press release as well as on expectations or beliefs regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenses. These assumptions may also be based on information obtained from third party industry analysts and other third party sources. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates which, although considered reasonable by Levitee Labs at the date on which such statements are made, are subject to risks, uncertainties, assumptions. and other known and unknown factors that may cause actual results, performance or achievements are materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risks associated with the following: history limited operations of Levitee Labs; the ability to secure additional funding; negative cash flow from operating activities since inception; regulatory requirements; changes in consumer preferences; supply of raw materials; the use of a limited number of products; brand awareness; the ability to develop, market and produce new products; dependence on certain key senior executives; the use of third parties for manufacturing and packaging; potential product liability claims and product recalls; and significant competition. For more information regarding these risks, please see the risk factors identified and reported in Levitee Labs’ public documents under its SEDAR profile at www.sedar.com. Any forward-looking information contained in this press release is expressly qualified by this cautionary statement. Readers are cautioned not to place undue reliance on forward-looking statements or information. Forward-looking information is made as of the date of this press release, and Levitee Labs assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. CSE (operated by CNSX Markets Inc.) has neither approved nor disapproved the contents of this press release and accepts no responsibility for the adequacy or accuracy of this press release.

For more information about Levitee Labs Inc., please contact:

Media contact:
[email protected]

Investor and corporate communication:
[email protected]

For more information about Adracare Inc., please contact:

Brittany Dubeck
[email protected]
1 (833) 533 0477


About Author

Comments are closed.